XERS: @ HC Wainwright Invest Conference 9/11/23

Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patients’ lives by developing and commercializing innovative products across a range of therapies, today announced that members of its senior management will participate in a fireside chat at the H.C. Wainwright 25 th Annual Global Investment Conference on Monday, September 11, 2023 at 9:30am Eastern Time.

A live webcast of the event will be available on the 'Events & Presentations' section of Xeris’ Investor Relations website at xerispharma.com/investor-relations or journey.ct.events/view/773cc0a3-0963-44b6-8523-1d257c8286d0 A replay of the webcast will be available for 60 days.

About Xeris

Xeris (Nasdaq: XERS) is a growth-oriented biopharmaceutical company committed to improving patients’ lives by developing and commercializing differentiated and innovative products across a range of therapies. Xeris has three commercially available products: Gvoke ® , a ready-to-use liquid glucagon for the treatment of severe hypoglycemia; Keveyis ® , a proven therapy for primary periodic paralysis; and Recorlev ® for the treatment of endogenous Cushing’s syndrome. Xeris has a pipeline of development and partnered programs using its formulation sciences, XeriSol™ and XeriJect™, to support long-term product development and commercial success.